Passive Immunotherapy of Infectious Diseases: Lessons from the Past, Directions for the Future
Publisher
Vieweg+Teubner Verlag
Reference17 articles.
1. Finland, M.: The serum treatment of lobar pneumonia. New England Journal of Medicine 1930, 202: 1244–1247.
2. Goodner, K., Miller, D. K.: The protective action of type I antipneumococcus serum in mice: II. The course of the infectious process. Journal of Experimental Medicine 1935, 62: 375–391.
3. Cross, A. S., Zollinger, W., Mandrell, R., Gemski, P., Sadoff, J.: Evaluation of immunotherapeutic approaches for the potential treatment of infections caused by Kl-positive Escherichia coli. Journal of Infectious Diseases 1983, 147:68–76.
4. Kurlander, R. J., Hall, J.: Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. Journal of Clinical Investigation 1986, 77: 2010–2018.
5. Finland, M.: Adequate dosage in the specific serum treatment of pneumococcus type I pneumonia. American Journal of Medical Science 1936, 192: 849–864.